purpose of glp 1 Glucagon-like peptide in health and disease Science Behind GLP 1 GIP
Description
doi:10.1038/s41419-017-0217-y 74
2 However, the majority of publications presented these results as a secondary outcome in studies targeting the GLP-1 RA effect on patients with diabetes and patients with obesity
Make sure people get sufficient nutrition and are not losing too much muscle mass, Isaacs says
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)
Age, longer duration of diabetes, glycemic control, obesity, hypertension, dyslipidemia, and diabetic nephropathy were all associated with increased risk for CVD
